Cameron D Thomas
Overview
Explore the profile of Cameron D Thomas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cavallari L, Lee C, Franchi F, Keeley E, Rossi J, Thomas C, et al.
Clin Transl Sci
. 2024 Aug;
17(8):e70004.
PMID: 39150361
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) is indicated after percutaneous coronary intervention (PCI) to reduce the risk of atherothrombotic events. Approximately...
2.
AlSaeed M, Thomas C, Franchi F, Keeley E, Duarte J, Gong Y, et al.
Clin Pharmacol Ther
. 2024 Jul;
116(5):1227-1230.
PMID: 39031256
The ABCD-GENE score was developed to predict poor response to clopidogrel and includes Age, Body mass index, Chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m),...
3.
Duarte J, Thomas C, Lee C, Huddart R, Agundez J, Baye J, et al.
Clin Pharmacol Ther
. 2024 Jul;
116(4):939-947.
PMID: 38951961
Beta-blockers are widely used medications for a variety of indications, including heart failure, myocardial infarction, cardiac arrhythmias, and hypertension. Genetic variability in pharmacokinetic (e.g., CYP2D6) and pharmacodynamic (e.g., ADRB1, ADRB2,...
4.
Tunehag K, Thomas C, Franchi F, Rossi J, Keeley E, Anderson R, et al.
J Am Heart Assoc
. 2024 Jun;
13(12):e033791.
PMID: 38874073
Background: Cytochrome P450 2C19 (CYP2C19) intermediate and poor metabolizer patients exhibit diminished clopidogrel clinical effectiveness after percutaneous coronary intervention (PCI). However, outcome studies to date have lacked racial diversity. Thus,...
5.
Thomas C, Franchi F, Rossi J, Keeley E, Anderson R, Beitelshees A, et al.
J Am Coll Cardiol
. 2024 Apr;
83(15):1370-1381.
PMID: 38599713
Background: An ABCD-GENE (age, body mass index, chronic kidney disease, diabetes, and CYP2C19 genetic variants) score ≥10 predicts reduced clopidogrel effectiveness, but its association with response to alternative therapy remains...
6.
Implementation of CYP2C19 genotyping to guide proton pump inhibitor use at an academic health center
Cicali E, Elchynski A, Thomas C, Alam B, Dalton R, Davis R, et al.
Am J Health Syst Pharm
. 2023 May;
80(15):994-1003.
PMID: 37166240
Purpose: To describe the implementation of CYP2C19 testing into clinical practice at University of Florida (UF) Health Gainesville hospital to guide proton pump inhibitor (PPI) dosing and the lessons learned...
7.
Wang Y, Cavallari L, Brown J, Thomas C, Winterstein A
JAMA Netw Open
. 2023 Apr;
6(4):e238585.
PMID: 37067798
Importance: A platelet ADP P2Y12 receptor (P2Y12) inhibitor plus aspirin is standard therapy for patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Compared with clopidogrel, prasugrel and...
8.
Thomas C, Williams A, Lee C, Cavallari L
Pharmacotherapy
. 2023 Jan;
43(2):158-175.
PMID: 36588476
Oral P2Y inhibitors are commonly prescribed for cardiovascular disease and include clopidogrel, prasugrel, and ticagrelor. Each of these drugs has its strengths and weaknesses. Prasugrel and ticagrelor are more potent...
9.
Cavallari L, Limdi N, Beitelshees A, Lee J, Duarte J, Franchi F, et al.
Clin Pharmacol Ther
. 2022 Oct;
113(3):615-623.
PMID: 36306392
Black patients suffer worse outcomes after percutaneous coronary intervention (PCI) than White patients. Inequities in antiplatelet prescribing may contribute to this health disparity. We compared P2Y inhibitor prescribing by race...
10.
Cavallari L, Cicali E, Wiisanen K, Fillingim R, Chakraborty H, Myers R, et al.
Clin Transl Sci
. 2022 Jul;
15(10):2479-2492.
PMID: 35899435
Opioid prescribing for postoperative pain management is challenging because of inter-patient variability in opioid response and concern about opioid addiction. Tramadol, hydrocodone, and codeine depend on the cytochrome P450 2D6...